Pharma
-
Prasad’s FDA appointment pressures cell and gene therapy stocks
A vocal opponent of his predecessor Peter Marks, Dr. Vinay Prasad will now lead the office tasked with reviewing some genetic medicines, adding more uncertainty to an already struggling field of research.
By Ben Fidler • May 7, 2025 -
With TV ads under threat, here’s how pharma can leverage social media
RFK Jr.’s plan to ban TV advertising may shift more marketing attention to online platforms.
By Amy Baxter • May 7, 2025 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
On tariffs and pricing, Big Pharma CEOs are waiting out the storm while planning for the worst
Chief executives at the largest drugmakers in the world are confident tariffs and pricing measures won’t be a major problem. But they’re still poised for change.
By Michael Gibney • May 6, 2025 -
After an up and down year, pharma’s R&D landscape is shifting again
While clinical trial funding was up, deal-making was down, and new uncertainties are coming into the picture.
By Kelly Bilodeau • May 5, 2025 -
With compounders out of the way, Lilly and Novo go after each other
The two obesity leaders are pulling on all levers to stay on top of the market.
By Amy Baxter • May 5, 2025 -
Is pharma ready to let go of animal testing?
Regulators have signaled their willingness to embrace alternative tests and guide the industry in new directions.
By Meagan Parrish • May 2, 2025 -
J&J scores FDA OK for immune drug touted as future blockbuster
The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in annual sales at its peak.
By Ned Pagliarulo • May 1, 2025 -
Q&A
Can real-world evidence bear some of the burden left by NIH cuts? This CEO sees an opportunity.
Turmoil at the NIH has led to handwringing among researchers and drugmakers who rely on public funding.
By Michael Gibney • May 1, 2025 -
Is the FDA headed for a major reorganization?
A leaked document revealed details about changes that could impact how the agency operates, but recent comments from FDA Commissioner Dr. Marty Makary have muddied the picture.
By Amy Baxter • April 30, 2025 -
FDA’s job cuts paint mixed picture for drugmakers’ R&D plans
After a 20% cut to the FDA’s workforce, biotechs and pharmas are bracing for delays. But the impacts won’t be consistent.
By Amy Baxter • April 28, 2025 -
Will Cobenfy’s clinical stumble derail a once-predicted rise?
BMS hopes to broaden the applications for the new schizophrenia drug into areas such as Alzheimer’s disease.
By Kelly Bilodeau • April 28, 2025 -
Trump reveals pharma reform priorities in drug pricing executive order
The order takes aim at fixing the IRA’s “pill penalty,” as well as PBM reform and other attempts to lower drug prices.
By Amy Baxter • April 23, 2025 -
Beyond the drug: Closing the knowledge gap for injectable diabetes meds
As the diabetes and weight loss market booms, more collaboration between pharma and medtech could help patients get the most out of injectable drugs.
By Michael Gibney • April 22, 2025 -
Genetic breakthroughs could point pharma to a long COVID drug
The discoveries also hold potential benefits for patients with other conditions, such as chronic fatigue syndrome.
By Kelly Bilodeau • April 22, 2025 -
Can anything threaten Novo and Lilly’s obesity market dominance?
Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back competition.
By Amy Baxter • April 21, 2025 -
How a scrapped Pfizer drug became a winner for SpringWorks
SpringWorks Therapeutics and the Children’s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.
By Alexandra Pecci • April 21, 2025 -
Deep Dive
HHS layoffs may be illegal, legal experts say
The federal health department sidestepped normal procedures as it laid off 10,000 employees, according to sources. One union has already filed an internal complaint, while at least two law firms are exploring suits.
By Rebecca Pifer • April 17, 2025 -
Novartis scores NFL deal to tackle health outcomes
The non-traditional marketing approach comes amid a potential crackdown on TV drug ads.
By Amy Baxter • April 17, 2025 -
Amid an onshoring push, Raleigh is poised to be pharma’s next manufacturing hub
Lower operating costs and a supply of high-skilled workers are helping the North Carolina region pull in billions of pharma manufacturing investments.
By Alexandra Pecci • April 16, 2025 -
The fallout from UnitedHealth’s CEO slaying
Brian Thompson’s murder has raised questions about the cost of U.S. healthcare, embroiling insurers, drugmakers and PBMs in a battle for the future of the industry.
By PharmaVoice staff • April 15, 2025 -
Pharma’s capital allocation could shift as tariffs threaten an already fragile profit model
Major changes to the dynamics of the pharmaceutical ecosystem are making executive decisions even tougher.
By Michael Gibney • April 14, 2025 -
Pharma’s US manufacturing moment: Where companies are making the biggest moves
The tariff war has prompted new calls to reshore manufacturing. Several large pharmas have already made the leap.
By Meagan Parrish • April 11, 2025 -
Trump’s tariff tirade and sudden calm keep Big Pharma on its toes
A wild ride in an escalating trade war has torn at Big Pharma’s shares while global markets flag in the back-and-forth winds.
By Michael Gibney • April 10, 2025 -
US risks losing biotech edge to China, report warns
“There will be a ChatGPT moment for biotechnology,” a bipartisan commission wrote in the new report, which calls for the U.S. to invest at least $15 billion into the sector over the next five years.
By Ned Pagliarulo • April 9, 2025 -
Big Pharma is rewriting the R&D playbook to account for seismic shifts in the investment landscape
The top 20 pharma companies are focusing on novel drugs, innovative dealmaking and playing to their strengths to bolster R&D ROI.
By Alexandra Pecci • April 9, 2025